{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:44:29Z","timestamp":1792737869225,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00228-026-04112-9","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:20:59Z","timestamp":1781850059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of different pharmacological therapies for diffuse cutaneous systemic sclerosis: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Xian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"10103","key":"4112_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/s0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685\u20131699. https:\/\/doi.org\/10.1016\/s0140-6736(17)30933-9","journal-title":"Lancet"},{"issue":"Suppl 1","key":"4112_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000782","volume":"4","author":"V Smith","year":"2018","unstructured":"Smith V, Scir\u00e8 CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M (2018) Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open 4(Suppl 1):e000782. https:\/\/doi.org\/10.1136\/rmdopen-2018-000782","journal-title":"RMD Open"},{"issue":"6","key":"4112_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/00002281-200111000-00011","volume":"13","author":"JR Seibold","year":"2001","unstructured":"Seibold JR (2001) Clinical trials: types, design, and end-points. Curr Opin Rheumatol 13(6):512\u2013515. https:\/\/doi.org\/10.1097\/00002281-200111000-00011","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"4112_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/art.1780290410","volume":"29","author":"RM Silver","year":"1986","unstructured":"Silver RM, Metcalf JF, LeRoy EC (1986) Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum 29(4):525\u2013531. https:\/\/doi.org\/10.1002\/art.1780290410","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4112_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1577-0","volume":"20","author":"M Cutolo","year":"2018","unstructured":"Cutolo M, Ruaro B, Montagna P, Brizzolara R, Stratta E, Trombetta AC, Scabini S, Tavilla PP, Parodi A, Corallo C, Giordano N, Paolino S, Pizzorni C, Sulli A, Smith V, Soldano S (2018) Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts. Arthritis Res Ther 20(1):77. https:\/\/doi.org\/10.1186\/s13075-018-1577-0","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"4112_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/keh671","volume":"44","author":"FA Wollheim","year":"2005","unstructured":"Wollheim FA (2005) Classification of systemic sclerosis. Visions and reality**dedicated to the memory of E. Carwile LeRoy, 1933\u20132002. Rheumatology (Oxford) 44(10):1212\u20131216. https:\/\/doi.org\/10.1093\/rheumatology\/keh671","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4112_CR7","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr., Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202\u2013205","journal-title":"J Rheumatol"},{"key":"4112_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4569826","volume":"2019","author":"A Sierra-Sep\u00falveda","year":"2019","unstructured":"Sierra-Sep\u00falveda A, Esquinca-Gonz\u00e1lez A, Benavides-Su\u00e1rez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Casta\u00f1eda AR, Rodr\u00edguez-Reyna TS (2019) Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast. Biomed Res Int 2019:4569826. https:\/\/doi.org\/10.1155\/2019\/4569826","journal-title":"Biomed Res Int"},{"issue":"1","key":"4112_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1872-4","volume":"21","author":"CP Denton","year":"2019","unstructured":"Denton CP, Murray C (2019) Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis. Arthritis Res Ther 21(1):81. https:\/\/doi.org\/10.1186\/s13075-019-1872-4","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"4112_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13238","volume":"195","author":"M Brown","year":"2019","unstructured":"Brown M, O\u2019Reilly S (2019) The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol 195(3):310\u2013321. https:\/\/doi.org\/10.1111\/cei.13238","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"4112_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102507","volume":"19","author":"M Rubio-Rivas","year":"2020","unstructured":"Rubio-Rivas M, Corbella X, Guill\u00e9n-Del-Castillo A, Tolosa Vilella C, Colunga Arg\u00fcelles D, Argibay A, Vargas Hitos JA, Todol\u00ed Parra JA, Gonz\u00e1lez-Ech\u00e1varri C, Ortego-Centeno N, Trapiella Mart\u00ednez L, Rodr\u00edguez Carballeira M, Mar\u00edn Ballv\u00e9 A, Pla Salas X, Perales Fraile I, Chamorro AJ, Madro\u00f1ero Vuelta AB, Freire M, Ruiz Mu\u00f1oz M, Gonz\u00e1lez Garc\u00eda A, Pons Mart\u00edn Del Campo I, S\u00e1nchez Garc\u00eda ME, Bernal Bello D, Espinosa G, Garc\u00eda Hern\u00e1ndez FJ, S\u00e1ez Comet L, R\u00edos Blanco JJ, Fern\u00e1ndez de la Puebla Gim\u00e9nez R, S\u00e1nchez Trigo S, Fonollosa Pla V, Sime\u00f3n Aznar CP (2020) Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: derivation and internal validation. Autoimmun Rev 19(5):102507. https:\/\/doi.org\/10.1016\/j.autrev.2020.102507","journal-title":"Autoimmun Rev"},{"issue":"9","key":"4112_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/art.40906","volume":"71","author":"V Sobanski","year":"2019","unstructured":"Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Air\u00f2 P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E (2019) Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis. Arthritis Rheumatol 71(9):1553\u20131570. https:\/\/doi.org\/10.1002\/art.40906","journal-title":"Arthritis Rheumatol"},{"key":"4112_CR13","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00235-2020","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Distler O (2021) Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00235-2020","journal-title":"ERJ Open Res"},{"issue":"5","key":"4112_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","volume":"79","author":"D Khanna","year":"2020","unstructured":"Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Be\u010dv\u00e1\u0159 R, Czirj\u00e1k L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Sz\u00fccs G, Truchetet ME, Wosnitza M, Laapas K, de Pena O, Yao J, Kramer Z, Distler F O (2020) Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis 79(5):618\u2013625. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216823","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4112_CR15","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/art.41294","volume":"72","author":"R Spiera","year":"2020","unstructured":"Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, Furst DE, Gordon J, Mayes M, Simms R, Lafyatis R, Martyanov V, Wood T, Whitfield ML, Constantine S, Lee E, Dgetluck N, White B (2020) Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol 72(8):1350\u20131360. https:\/\/doi.org\/10.1002\/art.41294","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"4112_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.42510","volume":"75","author":"R Spiera","year":"2023","unstructured":"Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyz\u0144ski P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP (2023) Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 75(9):1608\u20131618. https:\/\/doi.org\/10.1002\/art.42510","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"4112_CR17","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","volume":"79","author":"Y Allanore","year":"2020","unstructured":"Allanore Y, Wung P, Soubrane C, Esperet C, Marrache F, Bejuit R, Lahmar A, Khanna D, Denton CP (2020) A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis 79(12):1600\u20131607. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218447","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4112_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/s2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963\u2013974. https:\/\/doi.org\/10.1016\/s2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"issue":"5","key":"4112_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/rheumatology\/kez054","volume":"58","author":"G Sircar","year":"2019","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2019) Comment on: intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply. Rheumatology (Oxford) 58(5):925\u2013926. https:\/\/doi.org\/10.1093\/rheumatology\/kez054","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4112_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, \u010coli\u0107 J, Santiago T, Suliman YA, Matucci-Cerinic M, Gabrielli A, Distler O, Hoffmann-Vold AM, Castellv\u00ed I, Balbir-Gurman A, Vonk M, Ananyeva L, Rednic S, Tarasova A, Ostojic P, Boyadzhieva V, El Aoufy K, Farrington S, Galetti I, Denton CP, Kowal-Bielecka O, Mueller-Ladner U, Allanore Y (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340. https:\/\/doi.org\/10.1136\/ard-2024-226430","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4112_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/m14-2385","journal-title":"Ann Intern Med"},{"issue":"8","key":"4112_CR22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/art.42477","volume":"75","author":"D Khanna","year":"2023","unstructured":"Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S (2023) A 24-week, phase IIa, randomized, double-blind, placebo-controlled study of ziritaxestat in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 75(8):1434\u20131444. https:\/\/doi.org\/10.1002\/art.42477","journal-title":"Arthritis Rheumatol"},{"key":"4112_CR23","unstructured":"National Heart L, and Blood Institute (2013) Quality Assessment Tool for Controlled Intervention Studies. In: ed. National Institutes of Health"},{"issue":"9","key":"4112_CR24","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1093\/rheumatology\/kead012","volume":"62","author":"DJ Griffiths-Jones","year":"2023","unstructured":"Griffiths-Jones DJ, Garcia YS, Ryder WD, Pauling JD, Hall F, Lanyon P, Bhat S, Douglas K, Gunawardena H, Akil M, Anderson M, Griffiths B, Del Galdo F, Youssef H, Madhok R, Arthurs B, Buch M, Fligelstone K, Zubair M, Mason JC, Denton CP, Herrick AL (2023) A phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology (Oxford) 62(9):3133\u20133138. https:\/\/doi.org\/10.1093\/rheumatology\/kead012","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4112_CR25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","volume":"205","author":"D Khanna","year":"2022","unstructured":"Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP (2022) Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med 205(6):674\u2013684. https:\/\/doi.org\/10.1164\/rccm.202103-0714OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4112_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, M\u00fcller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77(2):212\u2013220. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211682","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4112_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","volume":"17","author":"EF Chakravarty","year":"2015","unstructured":"Chakravarty EF, Martyanov V, Fiorentino D, Wood TA, Haddon DJ, Jarrell JA, Utz PJ, Genovese MC, Whitfield ML, Chung L (2015) Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther 17(1):159. https:\/\/doi.org\/10.1186\/s13075-015-0669-3","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4112_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol 70(2):308\u2013316. https:\/\/doi.org\/10.1002\/art.40358","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"4112_CR29","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1136\/ard.2007.069518","volume":"66","author":"PJ Clements","year":"2007","unstructured":"Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE (2007) Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 66(12):1641\u20131647. https:\/\/doi.org\/10.1136\/ard.2007.069518","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4112_CR30","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O\u2019Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44(6):1351\u20131358 10.1002\/1529\u2009\u2013\u20090131(200106)44:6\u2009<\u20091351::Aid-art227\u2009>\u20093.0.Co;2-i","journal-title":"Arthritis Rheum"},{"issue":"113","key":"4112_CR31","first-page":"146","volume":"36","author":"JC Mantero","year":"2018","unstructured":"Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, Simms RW, Lafyatis R (2018) Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial. Clin Exp Rheumatol 36(113):146\u2013149","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"4112_CR32","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/art.24986","volume":"60","author":"TI Su","year":"2009","unstructured":"Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ (2009) Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 60(12):3821\u20133830. https:\/\/doi.org\/10.1002\/art.24986","journal-title":"Arthritis Rheum"},{"issue":"2 Suppl 76","key":"4112_CR33","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S (2013) A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 31(2 Suppl 76):151\u2013156","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"4112_CR34","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1093\/rheumatology\/keaf062","volume":"64","author":"L Chung","year":"2025","unstructured":"Chung L, Silver RM, Steen V, Furst DE, Castelino FV, Trojanowski M, Spiera R, Domsic R, Rodriguez-Pla A, Katsumoto TR, Goulaouic H, Wang H, Espinasse M, El-Chemaly S, Wang R (2025) Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study. Rheumatology (Oxford) 64(7):4299\u20134308. https:\/\/doi.org\/10.1093\/rheumatology\/keaf062","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4112_CR35","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/mr\/road040","volume":"33","author":"H Yoshifuji","year":"2023","unstructured":"Yoshifuji H, Yomono K, Yamano Y, Kondoh Y, Yasuoka H (2023) Role of rituximab in the treatment of systemic sclerosis: A literature review. Mod Rheumatol 33(6):1068\u20131077. https:\/\/doi.org\/10.1093\/mr\/road040","journal-title":"Mod Rheumatol"},{"key":"4112_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00272","volume":"6","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of Systemic Sclerosis. Front Immunol 6:272. https:\/\/doi.org\/10.3389\/fimmu.2015.00272","journal-title":"Front Immunol"},{"issue":"1","key":"4112_CR37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty D, \u0160umov\u00e1 B, Mallano T, Chen CW, Distler A, Bergmann C, Ludolph I, Horch RE, Gelse K, Ramming A, Distler O, Schett G, \u0160enolt L, Distler JHW (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8(1):1130. https:\/\/doi.org\/10.1038\/s41467-017-01236-6","journal-title":"Nat Commun"},{"issue":"6","key":"4112_CR38","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74(6):1188\u20131194. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204522","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4112_CR39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M Thiebaut","year":"2018","unstructured":"Thiebaut M, Launay D, Rivi\u00e8re S, Mah\u00e9vas T, Bellakhal S, Hachulla E, Fain O, Mekinian A (2018) Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev 17(6):582\u2013587. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.010","journal-title":"Autoimmun Rev"},{"issue":"10","key":"4112_CR40","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1007\/s10067-021-05785-6","volume":"40","author":"DD Y\u0131lmaz","year":"2021","unstructured":"Y\u0131lmaz DD, Borekci S, Musellim B (2021) Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. Clin Rheumatol 40(10):4071\u20134079. https:\/\/doi.org\/10.1007\/s10067-021-05785-6","journal-title":"Clin Rheumatol"},{"issue":"11","key":"4112_CR41","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48(11):3253\u20133265. https:\/\/doi.org\/10.1002\/art.11299","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4112_CR42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/s0923-1811(01)00128-1","volume":"27","author":"S Sato","year":"2001","unstructured":"Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27(2):140\u2013146. https:\/\/doi.org\/10.1016\/s0923-1811(01)00128-1","journal-title":"J Dermatol Sci"},{"issue":"2","key":"4112_CR43","first-page":"275","volume":"33","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33(2):275\u2013284","journal-title":"J Rheumatol"},{"issue":"2 Suppl 76","key":"4112_CR44","first-page":"122","volume":"31","author":"C Muangchant","year":"2013","unstructured":"Muangchant C, Pope JE (2013) The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol 31(2 Suppl 76):122\u2013134","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"4112_CR45","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3899\/jrheum.111423","volume":"39","author":"C Muangchan","year":"2012","unstructured":"Muangchan C, Pope JE (2012) Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 39(6):1120\u20131124. https:\/\/doi.org\/10.3899\/jrheum.111423","journal-title":"J Rheumatol"},{"issue":"9","key":"4112_CR46","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T (2018) Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 77(9):1362\u20131371. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213031","journal-title":"Ann Rheum Dis"},{"key":"4112_CR47","unstructured":"Del Galdo F (2024) Updated EULAR Recommendations on the Treatment of Systemic Sclerosis. In: ed. Medscape"},{"issue":"25","key":"4112_CR48","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"issue":"12","key":"4112_CR49","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962\u20133970. https:\/\/doi.org\/10.1002\/art.22204","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4112_CR50","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/s2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/s2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"45","key":"4112_CR51","first-page":"3641","volume":"95","author":"G Zhang","year":"2015","unstructured":"Zhang G, Xu T, Zhang H, Ye S, Wang Q, Zhang L, Lei Y, Luo R, Zhang X (2015) Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease. Zhonghua Yi Xue Za Zhi 95(45):3641\u20133645","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"4112_CR52","doi-asserted-by":"publisher","first-page":"w14030","DOI":"10.4414\/smw.2014.14030","volume":"144","author":"D Dan","year":"2014","unstructured":"Dan D, Fischer R, Adler S, F\u00f6rger F, Villiger PM (2014) Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. Swiss Med Wkly 144:w14030. https:\/\/doi.org\/10.4414\/smw.2014.14030","journal-title":"Swiss Med Wkly"},{"issue":"11","key":"4112_CR53","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1586\/1744666x.2014.962996","volume":"10","author":"P Cipriani","year":"2014","unstructured":"Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R (2014) Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol 10(11):1519\u20131530. https:\/\/doi.org\/10.1586\/1744666x.2014.962996","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"4112_CR54","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1172\/jci2676","volume":"102","author":"L Genestier","year":"1998","unstructured":"Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP (1998) Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102(2):322\u2013328. https:\/\/doi.org\/10.1172\/jci2676","journal-title":"J Clin Invest"},{"issue":"4","key":"4112_CR55","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/ar419","volume":"4","author":"ES Chan","year":"2002","unstructured":"Chan ES, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4(4):266\u2013273. https:\/\/doi.org\/10.1186\/ar419","journal-title":"Arthritis Res"},{"issue":"12","key":"4112_CR56","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.1969.03160250017003","volume":"209","author":"AM Clarysse","year":"1969","unstructured":"Clarysse AM, Cathey WJ, Cartwright GE, Wintrobe MM (1969) Pulmonary disease complicating intermittent therapy with methotrexate. JAMA 209(12):1861\u20131868","journal-title":"JAMA"},{"key":"4112_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221135314","volume":"16","author":"K Kim","year":"2022","unstructured":"Kim K, Woo A, Park Y, Yong SH, Lee SH, Lee SH, Leem AY, Kim SY, Chung KS, Kim EY, Jung JY, Kang YA, Kim YS, Park MS (2022) Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study. Ther Adv Respir Dis 16:17534666221135314. https:\/\/doi.org\/10.1177\/17534666221135314","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"4112_CR58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14740338.4.4.723","volume":"4","author":"O Lateef","year":"2005","unstructured":"Lateef O, Shakoor N, Balk RA (2005) Methotrexate pulmonary toxicity. Expert Opin Drug Saf 4(4):723\u2013730. https:\/\/doi.org\/10.1517\/14740338.4.4.723","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"4112_CR59","doi-asserted-by":"publisher","first-page":"L907","DOI":"10.1152\/ajplung.00120.2003","volume":"285","author":"DS Faffe","year":"2003","unstructured":"Faffe DS, Whitehead T, Moore PE, Baraldo S, Flynt L, Bourgeois K, Panettieri RA, Shore SA (2003) IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype. Am J Physiol Lung Cell Mol Physiol 285(4):L907-914. https:\/\/doi.org\/10.1152\/ajplung.00120.2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"4112_CR61","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01130-2018","author":"G Raghu","year":"2018","unstructured":"Raghu G, Richeldi L, Crestani B, Wung P, Bejuit R, Esperet C, Antoni C, Soubrane C (2018) SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01130-2018","journal-title":"Eur Respir J"},{"issue":"12","key":"4112_CR62","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","volume":"75","author":"M Ponsoye","year":"2016","unstructured":"Ponsoye M, Frantz C, Ruzehaji N, Nicco C, Elhai M, Ruiz B, Cauvet A, Pezet S, Brandely ML, Batteux F, Allanore Y, Avouac J (2016) Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis 75(12):2142\u20132149. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208213","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4112_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1652-6","volume":"20","author":"M Cutolo","year":"2018","unstructured":"Cutolo M, Soldano S, Montagna P, Trombetta AC, Contini P, Ruaro B, Sulli A, Scabini S, Stratta E, Paolino S, Pizzorni C, Smith V, Brizzolara R (2018) Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay. Arthritis Res Ther 20(1):157. https:\/\/doi.org\/10.1186\/s13075-018-1652-6","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"4112_CR64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Gali\u00e8 N, Grimminger F, Gr\u00fcnig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330\u2013340. https:\/\/doi.org\/10.1056\/NEJMoa1209655","journal-title":"N Engl J Med"},{"issue":"2","key":"4112_CR65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/13543784.2024.2305126","volume":"33","author":"J Simonetti","year":"2024","unstructured":"Simonetti J, Ficili M, Sgalla G, Richeldi L (2024) Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs 33(2):133\u2013143. https:\/\/doi.org\/10.1080\/13543784.2024.2305126","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"4112_CR66","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/s2213-2600(18)30181-4","volume":"6","author":"TM Maher","year":"2018","unstructured":"Maher TM, van der Aar EM, Van de Steen O, Allamassey L, Desrivot J, Dupont S, Fagard L, Ford P, Fieuw A, Wuyts W (2018) Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med 6(8):627\u2013635. https:\/\/doi.org\/10.1016\/s2213-2600(18)30181-4","journal-title":"Lancet Respir Med"},{"issue":"18","key":"4112_CR67","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/jama.2023.5355","volume":"329","author":"TM Maher","year":"2023","unstructured":"Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS (2023) Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis. JAMA 329(18):1567\u20131578. https:\/\/doi.org\/10.1001\/jama.2023.5355","journal-title":"JAMA"},{"issue":"Suppl 131","key":"4112_CR68","doi-asserted-by":"publisher","first-page":"124","DOI":"10.55563\/clinexprheumatol\/i80zh7","volume":"39","author":"R Spiera","year":"2021","unstructured":"Spiera R, Khanna D, Kuwana M, Furst DE, Frech TM, Hummers L, Stevens W, Matucci-Cerinic M, Baron M, Distler O, Dgetluck N, Bloom BJ, Dinh Q, White B, Denton CP (2021) A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clin Exp Rheumatol 39(Suppl 131):124\u2013133. https:\/\/doi.org\/10.55563\/clinexprheumatol\/i80zh7","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"4112_CR69","doi-asserted-by":"publisher","first-page":"103343","DOI":"10.1016\/j.retram.2022.103343","volume":"70","author":"F Ali","year":"2022","unstructured":"Ali F, Ilyas A (2022) Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease. Curr Res Transl Med 70(3):103343. https:\/\/doi.org\/10.1016\/j.retram.2022.103343","journal-title":"Curr Res Transl Med"},{"issue":"47","key":"4112_CR70","doi-asserted-by":"publisher","first-page":"16814","DOI":"10.1073\/pnas.1414189111","volume":"111","author":"A Zanin-Zhorov","year":"2014","unstructured":"Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky MV, Tonra J, Hippen KL, Dustin ML, Blazar BR, Liu CJ, Waksal SD (2014) Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A 111(47):16814\u201316819. https:\/\/doi.org\/10.1073\/pnas.1414189111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4112_CR71","doi-asserted-by":"publisher","first-page":"108823","DOI":"10.1016\/j.clim.2021.108823","volume":"230","author":"A Zanin-Zhorov","year":"2021","unstructured":"Zanin-Zhorov A, Blazar BR (2021) ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin Immunol 230:108823. https:\/\/doi.org\/10.1016\/j.clim.2021.108823","journal-title":"Clin Immunol"},{"issue":"10","key":"4112_CR72","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s10067-009-1202-3","volume":"28","author":"RB de Souza","year":"2009","unstructured":"de Souza RB, Macedo AR, Kuruma KA, Macedo PA, Borges CT (2009) Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis. Clin Rheumatol 28(10):1207\u20131212. https:\/\/doi.org\/10.1007\/s10067-009-1202-3","journal-title":"Clin Rheumatol"},{"issue":"8","key":"4112_CR73","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00296-010-1398-1","volume":"31","author":"P Ostojic","year":"2011","unstructured":"Ostojic P, Damjanov N (2011) Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis. Rheumatol Int 31(8):1051\u20131054. https:\/\/doi.org\/10.1007\/s00296-010-1398-1","journal-title":"Rheumatol Int"},{"issue":"17","key":"4112_CR74","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77(17):1865\u20131879. https:\/\/doi.org\/10.1007\/s40265-017-0829-7","journal-title":"Drugs"},{"issue":"4","key":"4112_CR75","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/acr2.1034","volume":"1","author":"TA Simon","year":"2019","unstructured":"Simon TA, Soule BP, Hochberg M, Fleming D, Torbeyns A, Banerjee S, Boers M (2019) Safety of abatacept versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials. ACR Open Rheumatol 1(4):251\u2013257. https:\/\/doi.org\/10.1002\/acr2.1034","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"4112_CR76","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3899\/jrheum.170344","volume":"45","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R (2018) Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial. J Rheumatol 45(8):1085\u20131092. https:\/\/doi.org\/10.3899\/jrheum.170344","journal-title":"J Rheumatol"},{"key":"4112_CR77","unstructured":"Administration USFD (2025) Orencia (abatacept) prescribing information. In: ed. U.S. Food and Drug Administration"},{"issue":"6","key":"4112_CR78","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s12026-018-9047-y","volume":"66","author":"M Lidar","year":"2018","unstructured":"Lidar M, Masarwa S, Rotman P, Carmi O, Rabinowicz N, Levy Y (2018) Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature. Immunol Res 66(6):668\u2013674. https:\/\/doi.org\/10.1007\/s12026-018-9047-y","journal-title":"Immunol Res"},{"issue":"2","key":"4112_CR79","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/s2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C, Raimondo MG, Chenguiti Fakhouri S, Atzinger A, Coppers B, Eckstein M, Liphardt AM, B\u00e4uerle T, Tascilar K, Aigner M, Kretschmann S, Wirsching A, Taubmann J, Hagen M, Gy\u00f6rfi AH, Kharboutli S, Krickau T, Dees C, Sp\u00f6rl S, Rothe T, Harrer T, Bozec A, Grieshaber-Bouyer R, Fuchs F, Kuwert T, Berking C, Horch RE, Uder M, Mackensen A, Schett G, Bergmann C (2025) CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol 7(2):e83\u2013e93. https:\/\/doi.org\/10.1016\/s2665-9913(24)00282-0","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"4112_CR80","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/acr.24785","volume":"75","author":"L Keyes-Elstein","year":"2023","unstructured":"Keyes-Elstein L, Pinckney A, Goldmuntz E, Welch B, Franks JM, Martyanov V, Wood TA, Crofford L, Mayes M, McSweeney P, Nash R, Georges G, Csuka ME, Simms R, Furst D, Khanna D, Clair EWS, Whitfield ML, Sullivan KM (2023) Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data. Arthritis Care Res (Hoboken) 75(2):307\u2013316. https:\/\/doi.org\/10.1002\/acr.24785","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4112_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102211","volume":"64","author":"H Bukiri","year":"2022","unstructured":"Bukiri H, Volkmann ER (2022) Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 64:102211. https:\/\/doi.org\/10.1016\/j.coph.2022.102211","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"4112_CR82","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.55563\/clinexprheumatol\/is29he","volume":"42","author":"G Lepri","year":"2024","unstructured":"Lepri G, Di Battista M, Codullo V, Bonomi F, Sulis A, Guiducci S, Della Rossa A (2024) Systemic sclerosis: one year in review 2024. Clin Exp Rheumatol 42(8):1517\u20131528. https:\/\/doi.org\/10.55563\/clinexprheumatol\/is29he","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"4112_CR83","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/s2665-9913(20)30237-x","volume":"2","author":"L Chung","year":"2020","unstructured":"Chung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, Steen VD, Lafyatis R, Simms RW, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Sandorfi N, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Allanore Y, Matucci-Cerinic M, Whitfield ML, Distler O, Singer O, Young A, Nagaraja V, Fox DA, Furst DE, Khanna D (2020) Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol 2(12):e743\u2013e753. https:\/\/doi.org\/10.1016\/s2665-9913(20)30237-x","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"4112_CR84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE (2020) Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol 72(1):125\u2013136. https:\/\/doi.org\/10.1002\/art.41055","journal-title":"Arthritis Rheumatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04112-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04112-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04112-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:30Z","timestamp":1783929450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04112-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4112"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04112-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}